ELTROMBOPAG
Information current as at: 1 October 2026
Submission Details
- Brand name:
-
- Revolade®
- Form and strength:
-
- Tablet 75 mg (as olamine)
- Submission sponsor:
- NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
- Condition/indication:
(therapeutic use) -
- Severe aplastic anaemia Severe thrombocytopenia
- Listing requested:
- To request listing of a new 75 mg strength of eltrombopag for the treatment of patients with severe aplastic anaemia and severe thrombocytopenia under the same restrictions as the currently listed tablet forms.
- Funding program:
- PBS Section 100 (Highly Specialised Drugs Program)
- Request authority level:
- Authority Required (Written or Telephone/Online)
- PBAC Submission type:
- New PBS listing (Category 4)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
PBAC meeting: - Held on 08/07/2026
-
Lodgement of required documentation: - 21/08/2026
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 09/09/2026
-
Status:
- Finalised
-
7Government processes:
- Commenced on 09/09/2026
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
The PBAC recommended the listing of eltrombopag 75 mg tablets for severe thrombocytopenia and severe aplastic anaemia on the Section 100 Highly Specialised Drugs Program under the same circumstances as the eltrombopag 25 mg and 50 mg listed strengths. The PBAC welcomed input from individuals and organisations describing the benefits of a 75 mg tablet in supporting medication management for patients with complex dosing schedules. The PBAC recommended that the new eltrombopag 75 mg dosage strength have a price that is equivalent on a per-milligram basis to the PBS-listed eltrombopag dosage strengths. The PBAC accepted the estimated financial impact of the new listing but noted there may be some minor costs to the R/PBS due to changes in co-payments.